Comment
doi: 10.1007/s00259-001-0713-1.
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis
- PMID: 11926391
- DOI: 10.1007/s00259-001-0713-1
Item in Clipboard
Comment
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis
Eur J Nucl Med Mol Imaging.
2002 Feb.
No abstract available
Comment in
-
Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl.Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1099-1100. doi: 10.1007/s00259-002-0864-8. Eur J Nucl Med Mol Imaging. 2002. PMID: 12296284 No abstract available.
-
90Y-DOTATOC and nephrotoxicity.Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1543. doi: 10.1007/s00259-002-0935-x. Eur J Nucl Med Mol Imaging. 2002. PMID: 12537003 No abstract available.
Comment on
-
End-stage renal disease after treatment with 90Y-DOTATOC.Eur J Nucl Med. 2001 Oct;28(10):1552-4. doi: 10.1007/s002590100599. Eur J Nucl Med. 2001. PMID: 11685499
-
Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney.Eur J Nucl Med. 2001 Oct;28(10):1447-9. doi: 10.1007/s002590100597. Eur J Nucl Med. 2001. PMID: 11688660 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
